Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | PLK1 | P53350 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | TYK2 | P29597 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221102 | 0.78 | CDC25B (0.43) | HSD17B10AURKAEGFRGSK3AGSK3B | |
| SCHEMBL4049191 | 0.76 | MEN1 (0.61) | HSD17B10MAPK8MAPK1JAK2TYK2 | |
| SCHEMBL301187 | 0.75 | MAPK8 (0.41) | MAPK8CHEK1PAK4CDK2MAPK1 | |
| SCHEMBL4223368 | 0.75 | GSK3A (0.51) | MAPK1GSK3AGSK3BCDK5NR1I2 | |
| SCHEMBL654384 | 0.74 | RAB9A (0.52) | TYK2JAK1PDPK1PIM1FGFR1 | |
| SCHEMBL1749409 | 0.74 | ALDH1A1 (0.41) | HSD17B10AURKAJAK2TYK2JAK3 | |
| SCHEMBL300795 | 0.74 | KDM4E (0.59) | HSD17B10MAPK1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4228405 | 0.73 | HSD17B10 (0.45) | HSD17B10AURKAGSK3AGSK3BCDK5 | |
| SCHEMBL4230926 | 0.71 | CSNK1D (0.46) | HSD17B10ABCB1ABCG2CSNK1D | |
| SCHEMBL27775430 | 0.68 | XDH (0.50) | MAPK8CHEK1PAK4CDK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | HSD17B10 1113/4885MAPK8 358/4885CHEK1 12/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | HSD17B10 1007/4885MAPK8 244/4885CHEK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.